Enterprise Value
90.33M
Cash
54.82M
Avg Qtr Burn
-20.7M
Short % of Float
5.70%
Insider Ownership
1.88%
Institutional Own.
52.99%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Brexafemme (Ibrexafungerp) Details Vulvovaginal Candidiasis | Approved Quarterly sales | |
Ibrexafungerp Details Fungal infections | Approved Quarterly sales |